Static Image
Victory for Maryland! Biosimilar Bill Signed by the Governor!

Victory for Maryland! Biosimilar Bill Signed by the Governor!

We applaud Maryland Governor Larry Hogan for joining 28 other states in creating a pathway for the substitution of biologic medications with biosimilars by signing the Pharmacists – Substitution and Dispensing of Biological Products bill into law. Biologics are life altering drugs for people with arthritis and are very complex products made with living cells. Because of this complexity they are expensive. Biosimilars, are a new class of drugs that are similar to biologics. They have the potential to lower medication costs. This new legislation creates a pathway that allows for the substitution of biologics with safe and effective interchangeable biologic products ...more
Researchers on the Path to a Cure - Spotlight on Dr. Martin Kriegel

Researchers on the Path to a Cure - Spotlight on Dr. Martin Kriegel

Trillions of bacteria live in or on your body. There are actually as many bacteria in your body as cells in your body. Fortunately, for most of us, most bacteria that live within us are helpful, not harmful. We call these bacteria commensal bacteria. Dr. Martin Kriegel and his team have been studying these bacteria, and more specifically, a protein that humans and bacteria produce, called Ro60, that plays a role in the development of lupus. Ro60 is a major target in lupus patients. It is one of the first proteins that antibodies recognize in healthy people who are predisposed to ...more
Arthritis Foundation Statement on the Official FY 2018 President’s Budget Request

Arthritis Foundation Statement on the Official FY 2018 President’s Budget Request

Today, the president released the administration's official budget request for fiscal year (FY) 2018, which would make deep cuts to health programs across health agencies and would have severe implications for Medicaid and other programs that deliver vital health care services to people with arthritis. While the Arthritis Foundation agrees that health care reform is necessary and our country needs to make important spending decisions, it should not be at the expense of people with arthritis, which now affects one in four Americans and the prevalence is growing. Specifically, this budget would cut nearly $6 billion from the National Institutes of ...more
California Advocates Work for Passage of Bill That Will Improve Continuity of Care When Insurance Carrier Changes

California Advocates Work for Passage of Bill That Will Improve Continuity of Care When Insurance Carrier Changes

It’s not uncommon for patients to change their insurance carriers. Sometimes it’s by choice, perhaps because they find a carrier that better suits their needs. Other times, it might be out of their control, like when their employment changes. Regardless of why carriers are changed, should patients be required to restart the utilization management process with their new insurance carrier, essentially starting over and potentially undoing years of effective and consistent care? On May 8, 2017, we joined forces with the California Rheumatology Alliance and the National Psoriasis Foundation for our annual California Advocacy Summit. This event provided the opportunity for our Advocates ...more
Study Confirms That Losing Weight May Save Your Knees

Study Confirms That Losing Weight May Save Your Knees

Losing excess weight may help preserve knee cartilage in people who have or are at risk of knee osteoarthritis (OA), according to researchers at the University of California, San Francisco (UCSF), whose findings were recently published online in the journal Radiology. Knee cartilage is the rubbery, slick cap that covers the ends of the upper (femur) and lower (tibia) leg bones that make up the knee joint. Their study also found that shedding extra pounds protected the menisci, the crescent-shaped cartilage pads that cushion the knee joint. Lead author Alexandra Gersing, MD, a postdoctoral scholar at UCSF School of Medicine, says ...more
FDA Approves Second Remicade biosimilar

FDA Approves Second Remicade biosimilar

The U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab), making it the fourth biosimilar approved to treat inflammatory types of arthritis. Renflexis is the second approved biosimilar to Remicade. The first one, Inflectra (infliximab-dyyb), was approved in April 2016. This is the first time the FDA has approved two biosimilars for one original, “reference” medication. Renflexis, manufactured by Samsung Bioepis, is a TNF (tumor necrosis factor) inhibitor, also called an anti-TNF, and is given by intravenous infusion. It is approved to treat the same conditions as Remicade – rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque ...more
Share Your Story! Help Us Raise Awareness this Arthritis Awareness Month

Share Your Story! Help Us Raise Awareness this Arthritis Awareness Month

More than 50 million Americans have arthritis – that’s one in four people. It’s currently the nation’s number one cause of disability. But this month—with your help— we're fighting back with the #FightFor50 campaign! To participate, we are asking that you share your story — tell us about your personal fight with arthritis, or tell us about a person you are fighting for, whether it's parent, grandparent, sibling, partner or a friend. While you’re there, check out the over 500 stories that have already been shared. Arthritis knows no boundaries. In our story bank, you'll find stories from young and old, people who ...more
Creating a Legacy to Conquer Arthritis

Creating a Legacy to Conquer Arthritis

Early in life while mowing lawns, growing and selling tomatoes and managing a neighborhood McDonald’s restaurant as a junior in high school, Kevin Mandrell always knew he had a natural knack for business. He was surrounded by strong business leaders and felt drawn from an early age to dive into business on his own. In 1984 he married the girl of his dreams and started a family. By the early 1990s he was busy keeping up with his young family while starting a new insurance firm when he was contacted by the local leader of the Arthritis Foundation office in Indianapolis ...more
Researchers on the Path to a Cure - Spotlight on Dr. Rae Yeung

Researchers on the Path to a Cure - Spotlight on Dr. Rae Yeung

Dr. Rae Yeung believes in collaboration and building networks to solve problems. Her current 3-year Arthritis Foundation-funded project, “Precision Decisions to STOP JIA”, is an example of that. The goal is to develop a tool that will predict treatment response to specific drugs. Dr. Yeung’s study focuses on a group of high-risk children with polyarthritis, one of the most severe forms of childhood arthritis that affects many joints and is difficult to treat. The aim of the study is to identify unique patterns of patient symptoms and biomarkers that, when considered together, will predict how a child with arthritis may react ...more
Researchers on the Path to a Cure - Spotlight on Dr. Bruce Cronstein

Researchers on the Path to a Cure - Spotlight on Dr. Bruce Cronstein

This story started with a dozen male research mice survivors from hurricane Sandy in 2012. The storm devastated Dr. Bruce Cronstein’s research lab, but born from the destruction was Dr. Cronstein’s 5-year Arthritis Foundation Investigator-funded project, “The Role of Adenosine Receptors in Osteoarthritis.” He described the damage: “Our labs were closed for nearly a year and a half. We lost a lot of our animal facilities. However, once a lot of the debris was cleared, we were able to go in and found that some of our mice had survived.” Dr. Cronstein and his team discovered that the rescued mice could no ...more